Market Trends of Global Auto-Injectors Industry
Rheumatoid Arthritis Expected to Hold Significant Market Share Over the Forecast Period
Rheumatoid arthritis (RA) is an autoimmune disease in which the body's immune system attacks the joints, causing inflammation of the synovium and swelling and pain in and around the joints. Arthritis primarily affects the elderly population, with females having a higher prevalence than males. According to the United Nations World Population Prospects 2020 report, 727 million people are living in the world aged 65 years or above, and this number is expected to become more than double by the year 2050. As arthritis is more prevalent in the geriatric population and increasing it boosts the segment over the forecast period.
According to several recent studies, the majority of the patients with rheumatoid arthritis who used an autoinjector for the treatment were observed to be comfortable using the device and even had better outcomes than those who had someone else administer injections. Additionally, the initiatives by the market players are also propelling the growth of the market. For Instance, in March 2022, NORDIC PHARMA, a SEVER Life Sciences company, submitted a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet for the treatment of severe disabling active rheumatoid arthritis (RA) and symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy). Approval of such drugs is expected to propel the growth of the market.
Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.
North America Expected to Dominate the Market Over the Forecast Period
North America is expected to hold a significant share of the global disposable auto-injectors market during the forecast period. The factors such as early adoption of technologically advanced products and product approvals as well rising prevalence of chronic diseases boost the market in the region. A high incidence of chronic diseases, such as cancers, boosts the market in the region. According to the Globocon 2020, the number of new cancer cases diagnosed was 2,281,658 in the United States in 2020, with 612,390 deaths. Among all cancers, breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809).
Furthermore, rising technological advancements, increasing entry of new players, and speedy adoption of advanced products are helping in the market growth in the United States. For example, in April 2020, Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. reported the availability of the autoinjector device for AJOVY (fremanezumab-vfrm) injection in the United States. AJOVY is indicated for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.
Thus, owing to the abovementioned factors, the North American region is expected to project growth over the forecast period.
